Alkem Laboratories Ltd expands its presence in high-growth therapeutic areas with the acquisition of Adroit Biomed and Bombay Ortho Industries. These acquisitions will enhance Alkem’s dermatology and cosmetology portfolio while expanding its footprint in the medical device sector.
Adroit Biomed acquisition
The company will acquire Adroit Biomed, a company specialising in dermatology and cosmetology, for Rs 140 crore in two tranches. The deal is expected to be finalised by April 1, 2025. This acquisition will enable Alkem to diversify its skincare and aesthetic medicine offerings, strengthening its presence in the dermatology market.
The company has established itself as a key player in skincare with an omnichannel reach that complements its distribution network. In FY24, the company reported a turnover of ₹53.55 crore. The final transaction value will be subject to adjustments related to debt, working capital, and other closing considerations.
Bombay Ortho acquisition
In a separate transaction, Alkem Laboratories will acquire Bombay Ortho Industries for Rs 147 crore, payable in four tranches. This deal is expected to be completed by June 30, 2025. Bombay Ortho Industries specialises in hip and knee implants, which are essential components of India’s expanding medical device industry.
Acquiring Bombay Ortho equips Alkem with in-house manufacturing, leveraging India’s growing demand for high-quality, cost-effective orthopaedic implants. As healthcare advances and orthopaedic surgeries rise, Alkem is well-positioned to capitalise on growing demand in the Medtech sector.
Expanding market presence
Despite economic challenges, Alkem Laboratories has maintained strong financial performance. In Q3FY25, net profit grew 6% year-on-year to Rs 641 crore, despite a 9% sequential decline. Revenue stood at Rs 3,467 crore, reflecting a 1.4% year-on-year growth, though it experienced a 2.3% quarter-on-quarter dip.
The pharmaceutical and cosmetics manufacturer is concentrating on diversifying its product line, particularly in the dermatology sector. The company just introduced a liposomal skin care serum using Duo-Lipo technology in India to treat facial hyperpigmentation.
The latest acquisitions are in line with Alkem’s long-term vision of expanding its reach across multiple therapeutic and technology sectors.